Literature DB >> 23233282

Development of probiotic tablets using microparticles: viability studies and stability studies.

J P Sousa e Silva1, Sérgio C Sousa, Paulo Costa, Emília Cerdeira, Maria H Amaral, José Sousa Lobo, Ana M Gomes, Maria M Pintado, Dina Rodrigues, Teresa Rocha-Santos, Ana C Freitas.   

Abstract

Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with Lactobacillus paracasei L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of L. paracasei L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of L. paracasei L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of L. paracasei L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated L. paracasei L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of L. paracasei L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of L. paracasei L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233282      PMCID: PMC3581639          DOI: 10.1208/s12249-012-9898-9

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  21 in total

Review 1.  Microencapsulation of probiotic bacteria: technology and potential applications.

Authors:  Kaila Kailasapathy
Journal:  Curr Issues Intest Microbiol       Date:  2002-09

Review 2.  Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea.

Authors:  F Cremonini; S Di Caro; E C Nista; F Bartolozzi; G Capelli; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2002-08       Impact factor: 8.171

3.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

Review 4.  Probiotics: from research to consumer.

Authors:  M Del Piano; L Morelli; G P Strozzi; S Allesina; M Barba; F Deidda; P Lorenzini; M Ballaré; F Montino; M Orsello; M Sartori; E Garello; S Carmagnola; M Pagliarulo; L Capurso
Journal:  Dig Liver Dis       Date:  2006-12       Impact factor: 4.088

5.  Efficacy of Lactobacillus GG as a Diarrheal Preventive in Travelers.

Authors: 
Journal:  J Travel Med       Date:  1997-03-01       Impact factor: 8.490

Review 6.  Taxonomy and important features of probiotic microorganisms in food and nutrition.

Authors:  W H Holzapfel; P Haberer; R Geisen; J Björkroth; U Schillinger
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

7.  β-Lactoglobulin tablets as a suitable vehicle for protection and intestinal delivery of probiotic bacteria.

Authors:  Jean-François Poulin; Romain Caillard; Muriel Subirade
Journal:  Int J Pharm       Date:  2010-12-01       Impact factor: 5.875

8.  Carboxymethyl high amylose starch (CM-HAS) as excipient for Escherichia coli oral formulations.

Authors:  Carmen Calinescu; Jérôme Mulhbacher; Eric Nadeau; John Morris Fairbrother; Mircea Alexandru Mateescu
Journal:  Eur J Pharm Biopharm       Date:  2005-05       Impact factor: 5.571

9.  Optimization of a formulation containing viable lactic acid bacteria.

Authors:  M Stadler; H Viernstein
Journal:  Int J Pharm       Date:  2003-04-30       Impact factor: 5.875

10.  The probiotic Lactobacillus GG may augment intestinal host defense by regulating apoptosis and promoting cytoprotective responses in the developing murine gut.

Authors:  Patricia W Lin; Tala R Nasr; Andrew J Berardinelli; Amrita Kumar; Andrew S Neish
Journal:  Pediatr Res       Date:  2008-11       Impact factor: 3.756

View more
  5 in total

Review 1.  Insights on the Critical Parameters Affecting the Probiotic Viability During Stabilization Process and Formulation Development.

Authors:  Sharda Gurram; Durgesh K Jha; Devanshi S Shah; Madhuri M Kshirsagar; Purnima D Amin
Journal:  AAPS PharmSciTech       Date:  2021-05-18       Impact factor: 3.246

2.  Use of dietary supplements in relation to urinary phthalate metabolite concentrations: Results from the National Health and Nutrition Examination Survey.

Authors:  Megan E Romano; Kelli O'Connell; Mengmeng Du; Colin D Rehm; Elizabeth D Kantor
Journal:  Environ Res       Date:  2018-12-17       Impact factor: 6.498

3.  Coating Lacticaseibacillus rhamnosus GG in Alginate Systems: an Emerging Strategy Towards Improved Viability in Orange Juice.

Authors:  Angela Bonaccorso; Nunziatina Russo; Alessia Romeo; Claudia Carbone; Maria Aurora Grimaudo; Carmen Alvarez-Lorenzo; Cinzia Randazzo; Teresa Musumeci; Cinzia Caggia
Journal:  AAPS PharmSciTech       Date:  2021-04-05       Impact factor: 3.246

Review 4.  Pharmaceutical Coating and Its Different Approaches, a Review.

Authors:  Ahmad Salawi
Journal:  Polymers (Basel)       Date:  2022-08-15       Impact factor: 4.967

5.  Extracellular vesicles have variable dose-dependent effects on cultured draining cells in the eye.

Authors:  Saray Tabak; Sofia Schreiber-Avissar; Elie Beit-Yannai
Journal:  J Cell Mol Med       Date:  2018-02-07       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.